Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

BACKGROUND: Availability of checkpoint inhibitors has created a paradigm shift in the management of patients with solid tumors. Despite this, most patients do not respond to immunotherapy, and there is considerable interest in developing combination therapies to improve response rates and outcomes....

Full description

Bibliographic Details
Main Authors: Adjei, A.A (Author), Aggarwal, C. (Author), Antonia, S. (Author), Arnaldez, F.I (Author), Atkinson, V. (Author), Baughman, J. (Author), Birnbaum, A. (Author), Bonvini, E. (Author), Cavallo, R. (Author), Cohen, R.B (Author), Ferris, R.L (Author), Ganju, V. (Author), Goldberg, S.M (Author), Hauke, R. (Author), Joshua, A.M (Author), Kalebasty, A.R (Author), Kaul, S. (Author), Lakhani, N.J (Author), Lou, Y. (Author), Moore, P.A (Author), P Zandberg, D. (Author), Peng, L. (Author), Prawira, A. (Author), Rahma, O. (Author), Seetharam, M. (Author), Tolcher, A. (Author), Vogelzang, N. (Author), Weickhardt, A. (Author), Zhang, X. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
clinical trials as topic
drug therapy, combination
head and neck neoplasms
immunotherapy
lung neoplasms
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items